The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer
Official Title: A Phase II, Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU-0059436 Given Orally Twice Daily in Patients With Advanced BRCA1- or BRCA2-associated Breast Cancer.
Study ID: NCT00494234
Brief Summary: The purpose of the study is to see if the drug KU-0059436 (olaparib) is effective and well tolerated in treating participants with measurable breast cancer gene (BRCA)1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists.
Detailed Description: This is a Phase II, open-label, non-comparative, international, multicenter study to assess the efficacy and safety of olaparib when given orally twice daily (bd) in participants with advanced BRCA1- or BRCA2- associated breast cancer. Two sequential participant cohorts will receive continuous oral olaparib in 28-day cycles. The first cohort will receive 400 mg bd and the second cohort will receive 100 mg bd.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Research Site, West Hollywood, California, United States
Research Site, Boston, Massachusetts, United States
Research Site, Melbourne, , Australia
Research Site, Randwick, , Australia
Research Site, Duarte, CA, Canada
Research Site, Kiel, , Germany
Research Site, Köln, , Germany
Research Site, München, , Germany
Research Site, Tel-Aviv, , Israel
Research Site, Hospitalet deLlobregat, , Spain
Research Site, Madrid, , Spain
Research Site, Lund, , Sweden
Research Site, Cambridge, , United Kingdom
Research Site, Edinburgh, , United Kingdom
Research Site, Fulham, , United Kingdom
Research Site, London, , United Kingdom
Research Site, Manchester, , United Kingdom
Name: James Carmichael, BSc, MBChB, MD, FRCP
Affiliation: KuDOS Pharmaceuticals Limited
Role: STUDY_DIRECTOR
Name: Andrew Tutt, PhD MRCP FRCR
Affiliation: Guy's and St Thomas's NHS Foundation Trust, London, UK
Role: PRINCIPAL_INVESTIGATOR